MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Quanterix Corporation Cost of Revenue 2011-2026 | QTRX
Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.What is included in the cost of revenue
| Cost Category | Examples |
|---|---|
| Production Costs | Materials, wages of production staff, depreciation of equipment |
| Service and Support | Customer service, user support, technical assistance |
| Delivery and Logistics | Packaging, delivery of goods to customers |
| Hosting and Infrastructure | Servers, cloud platforms (especially for IT and SaaS companies) |
| Content and Licenses | License purchases, production royalties (e.g., in streaming services) |
Importance of the Metric
- Helps to understand how costly the revenue-generating process is.
- A high cost of revenue may indicate:
Poor cost control
Low operational efficiency - A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.
Annual Cost of Revenue Quanterix Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 73.9 M | 54.3 M | 48.1 M | 58.7 M | 48.8 M | 38.2 M | 29.9 M | 19.7 M | 12.9 M | 9.84 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 73.9 M | 9.84 M | 39.4 M |
Quarterly Cost of Revenue Quanterix Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 23 M | 13.2 M | 13.9 M | - | 15.7 M | 12.1 M | 13.5 M | - | 11.9 M | 11.5 M | - | 15.7 M | 14.8 M | 15 M | - | 12.4 M | 11.5 M | 10.9 M | 11.1 M | 10.3 M | 7.92 M | 8.91 M | 9.05 M | 7.91 M | 6.6 M | 6.33 M | 5.67 M | 5 M | 4.67 M | 4.35 M | - | 3.17 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 23 M | 3.17 M | 10.6 M |
Cost of Revenue of other stocks in the Medical devices industry
| Issuer | Cost of Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Bruker Corporation
BRKR
|
1.72 B | $ 39.25 | -0.58 % | $ 5.85 K |  USA |
 |
Align Technology
ALGN
|
1.2 B | $ 185.82 | -0.38 % | $ 13.9 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
76 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
5.7 M | - | 1.37 % | $ 20.5 M | USA |
 |
BioSig Technologies
BSGM
|
57 K | - | 37.08 % | $ 85.7 M | USA |
 |
Acutus Medical
AFIB
|
10.3 M | - | -26.83 % | $ 2.62 M | USA |
 |
Conformis
CFMS
|
38.8 M | - | - | $ 16.4 M | USA |
 |
Avinger
AVGR
|
5.65 M | - | -20.74 % | $ 369 K | USA |
 |
AdaptHealth Corp.
AHCO
|
2.64 B | $ 12.62 | -0.28 % | $ 1.71 B | USA |
 |
Allied Healthcare Products
AHPI
|
24.5 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cytosorbents Corporation
CTSO
|
10.6 M | $ 0.61 | 3.15 % | $ 38 M | USA |
 |
EDAP TMS S.A.
EDAP
|
37.6 M | $ 3.57 | 1.42 % | $ 134 M |  France |
 |
LENSAR
LNSR
|
31.3 M | $ 5.92 | -5.36 % | $ 70.8 M | USA |
 |
Boston Scientific Corporation
BSX
|
6.22 B | $ 63.96 | -1.01 % | $ 94.7 B | USA |
 |
Apollo Endosurgery
APEN
|
34.4 M | - | - | $ 475 M | USA |
 |
Cardiovascular Systems
CSII
|
63.4 M | - | 0.15 % | $ 844 M | USA |
 |
Eargo
EAR
|
23 M | - | - | $ 10.2 M | USA |
 |
ClearPoint Neuro
CLPT
|
14.3 M | $ 10.57 | 1.0 % | $ 299 M | USA |
 |
Dynatronics Corporation
DYNT
|
21.4 M | - | 14.99 % | $ 929 K | USA |
 |
Electromed
ELMD
|
14 M | $ 25.34 | -1.46 % | $ 214 M | USA |
 |
Second Sight Medical Products
EYES
|
11.4 M | - | -0.97 % | $ 54.4 M | USA |
 |
Sintx Technologies
SINT
|
557 K | $ 2.69 | -1.82 % | $ 7.46 M | USA |
 |
GBS
GBS
|
1.81 M | - | -0.57 % | $ 7.12 M | USA |
 |
Neovasc
NVCN
|
556 K | - | - | $ 111 M |  Canada |
 |
Stryker Corporation
SYK
|
9.05 B | $ 337.06 | -1.22 % | $ 129 B | USA |
 |
OrthoPediatrics Corp.
KIDS
|
63.7 M | $ 16.75 | -6.16 % | $ 393 M | USA |
 |
Globus Medical
GMED
|
958 M | $ 92.66 | -2.0 % | $ 12.5 B | USA |
 |
Tactile Systems Technology
TCMD
|
79.4 M | $ 24.94 | -1.62 % | $ 570 M | USA |
 |
TELA Bio
TELA
|
25.6 M | $ 0.65 | -0.61 % | $ 30.5 M | USA |
 |
Helius Medical Technologies
HSDT
|
583 K | $ 1.98 | 2.06 % | $ 1.2 M | USA |
 |
Butterfly Network
BFLY
|
33.2 M | $ 5.58 | 14.81 % | $ 1.18 B | USA |
 |
Tandem Diabetes Care
TNDM
|
469 M | $ 20.2 | -2.23 % | $ 1.37 B | USA |
 |
Inogen
INGN
|
194 M | $ 6.52 | 5.16 % | $ 173 M | USA |
 |
IRIDEX Corporation
IRIX
|
33.4 M | $ 1.03 | -0.96 % | $ 17.4 M | USA |
 |
BIOLASE
BIOL
|
32.4 M | - | -13.19 % | $ 166 K | USA |
 |
Delcath Systems
DCTH
|
11.8 M | $ 10.83 | -1.46 % | $ 388 M | USA |
 |
Inspire Medical Systems
INSP
|
133 M | $ 56.99 | 0.62 % | $ 1.67 B | USA |
 |
CONMED Corporation
CNMD
|
624 M | $ 38.09 | -3.42 % | $ 1.18 B | USA |
 |
LivaNova PLC
LIVN
|
448 M | $ 64.69 | -0.69 % | $ 3.53 B |  Britain |
 |
Integer Holdings Corporation
ITGR
|
1.35 B | $ 88.52 | 0.66 % | $ 3.07 B | USA |